ZVRA · Zevra Therapeutics, Inc. · Earnings Call Transcripts & Audio
$10.97
-0.37 (-3.26%)
At close · Sep 30
Return incl. dividend (before tax)
Market Cap
$648.17M
Shares
59.38M
Volume · Sep 30
1.82M
Avg daily vol (3M)
1.16M
Zevra Therapeutics, Inc. Earnings Call Transcripts
Quarterly earnings calls for Zevra Therapeutics, Inc. (ZVRA), with available speaker-labelled transcripts, captured audio replays, call highlights, 8-K earnings releases and periodic filings. Investor days and conferences appear here too.
Revenue & result across quarters
Revenue Net income YoY up YoY down artefacts
▲46.3%
$2.87M
−$6.62M
'22 Q3
22-11-09
▼21.7%
$2.02M
$5.75M
'22 Q4
23-01-25
▼19.9%
$3.18M
−$13.22M
'23 Q1
23-05-15
▲551.5%
$8.47M
−$2.57M
'23 Q2
23-08-14
▲0.7%
$2.90M
−$10.37M
'23 Q3
23-11-07
▲539%
$12.92M
−$19.89M
'23 Q4
24-03-28
▲7.8%
$3.42M
−$16.62M
'24 Q1
24-05-08
▼47.5%
$4.45M
−$19.93M
'24 Q2
24-08-08
▲27.6%
$3.69M
−$33.23M
'24 Q3
24-11-12
▼6.8%
$12.04M
−$35.74M
'24 Q4
25-03-11
▲495.6%
$20.40M
−$3.10M
'25 Q1
25-05-13
▲481.7%
$25.88M
$74.71M
'25 Q2
25-08-12
▲605.4%
$26.06M
−$544,000
'25 Q3
25-11-05
▲183.4%
$34.12M
$12.16M
'25 Q4
26-03-09
▲77.5%
$36.22M
$37.89M
'26 Q1
26-05-06
LATEST
▲53.3%
$39.66M
$8.75M
'26 Q2
26-08-05
Conference
Investor event
2026-09-14
Zevra Therapeutics, Inc. (ZVRA) September 2026 Conference Transcript
No reported result — non-financial event
Audio
Transcript
Slides
Conference
Investor event
2026-08-11
Zevra Therapeutics, Inc. (ZVRA) August 2026 Conference Transcript
No reported result — non-financial event
Audio
Transcript
Slides
Earnings call
FY26 · Q2
2026-08-05
Zevra Therapeutics, Inc. (ZVRA) Q2 2026 Earnings Call Transcript
Confident tone
European MAA reexamination (CHMP negative opinion)
Capital allocation / business development strategy
Financial strength and cash position
Revenue
$39.66M
▲ 53.3% YoY Diluted EPS
$0.14
▼ 88.4% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Conference
Investor event
2026-05-19
Zevra Therapeutics, Inc. (ZVRA) May 2026 Conference Transcript
No reported result — non-financial event
Audio
Transcript
Slides
Earnings call
FY26 · Q1
2026-05-06
Zevra Therapeutics, Inc. (ZVRA) Q1 2026 Earnings Call Transcript
Confident tone
MyPlifer (miglustat/aramcholamol) U.S. launch
Celiprolol DISCOVER Phase III trial for VEDS
Reimbursement and channel dynamics
Revenue
$36.22M
▲ 77.5% YoY Diluted EPS
$0.60
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY25 · Q4
2026-03-09
Zevra Therapeutics, Inc. (ZVRA) Q4 2025 Earnings Call Transcript
Confident tone
NPC patient identification and diagnosis
European expansion and MAA
MyPlypha commercial performance
Revenue
$34.12M*
▲ 183.4% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-K
Earnings call
FY25 · Q3
2025-11-05
Zevra Therapeutics, Inc. (ZVRA) Q3 2025 Earnings Call Transcript
Confident tone
MIPLYFFA commercial performance in NPC
Gross-to-net and Medicare Part D adjustment
European expansion and MAA
Revenue
$26.06M
▲ 605.4% YoY Diluted EPS
$-0.01
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY25 · Q2
2025-08-12
Zevra Therapeutics, Inc. (ZVRA) Q2 2025 Earnings Call Transcript
Confident tone
European expansion (MAA submission)
Reimbursement / payer coverage
Diagnosis awareness / patient identification
Revenue
$25.88M
▲ 481.7% YoY Diluted EPS
$1.21
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY25 · Q1
2025-05-13
Zevra Therapeutics, Inc. (ZVRA) Q1 2025 Earnings Call Transcript
Confident tone
Soliprolol / DISCOVER Phase 3 trial
Olpruva (UCDs) commercial strategy
Financial strength / PRV monetization
Revenue
$20.40M
▲ 495.6% YoY Diluted EPS
$-0.06
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY24 · Q4
2025-03-11
Zevra Therapeutics, Inc. (ZVRA) Q4 2024 Earnings Call Transcript
Confident tone
Reimbursement and access
Market expansion / patient identification
Financial position and capital allocation
Revenue
$12.04M*
▼ 6.8% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-K
Earnings call
FY24 · Q3
2024-11-12
Zevra Therapeutics, Inc. (ZVRA) Q3 2024 Earnings Call Transcript
Positive tone
MIPLYFFA launch
European regulatory expansion
Guidance and revenue timing
Revenue
$3.69M
▲ 27.6% YoY Diluted EPS
$-0.69
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY24 · Q2
2024-08-08
Zevra Therapeutics, Inc. (ZVRA) Q2 2024 Earnings Call Transcript
Confident tone
Arimoclomol FDA review and PDUFA
Expanded Access Program transition
OLPRUVA launch progress
Revenue
$4.45M
▼ 47.5% YoY Diluted EPS
$-0.48
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY24 · Q1
2024-05-08
Zevra Therapeutics, Inc. (ZVRA) Q1 2024 Earnings Call Transcript
Positive tone
Arimoclomol Regulatory Review
OLPRUVA Commercial Launch
KP1077 in Sleep Disorders
Revenue
$3.42M
▲ 7.8% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY23 · Q4
2024-03-28
Zevra Therapeutics, Inc. (ZVRA) Q4 2023 Earnings Call Transcript
Positive tone
Arimoclomol NDA and FDA review
OLPRUVA commercial launch
KP1077 in idiopathic hypersomnia
Revenue
$12.92M*
▲ 539% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-K
Earnings call
FY23 · Q3
2023-11-07
Zevra Therapeutics, Inc. (ZVRA) Q3 2023 Earnings Call Transcript
Revenue
$2.90M
▲ 0.7% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY23 · Q2
2023-08-14
Zevra Therapeutics, Inc. (ZVRA) Q2 2023 Earnings Call Transcript
Revenue
$8.47M
▲ 551.5% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY23 · Q1
2023-05-15
Zevra Therapeutics, Inc. (ZVRA) Q1 2023 Earnings Call Transcript
Revenue
$3.18M
▼ 19.9% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY22 · Q4
2023-01-25
Zevra Therapeutics, Inc. (ZVRA) Q4 2022 Earnings Call Transcript
Revenue
$2.02M*
▼ 21.7% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-K
Earnings call
FY22 · Q3
2022-11-09
Zevra Therapeutics, Inc. (ZVRA) Q3 2022 Earnings Call Transcript
Revenue
$2.87M
▲ 46.3% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY22 · Q2
2022-08-11
Zevra Therapeutics, Inc. (ZVRA) Q2 2022 Earnings Call Transcript
Revenue
$1.30M
▼ 89.2% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY22 · Q1
2022-05-12
Zevra Therapeutics, Inc. (ZVRA) Q1 2022 Earnings Call Transcript
Revenue
$3.96M
▼ 67.3% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY21 · Q4
2022-03-30
Zevra Therapeutics, Inc. (ZVRA) Q4 2021 Earnings Call Transcript
Revenue
$2.58M*
▲ 9.1% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-K
Earnings call
FY21 · Q3
2021-11-10
Zevra Therapeutics, Inc. (ZVRA) Q3 2021 Earnings Call Transcript
Revenue
$1.97M
▲ 2.1% YoY Diluted EPS
$-0.06
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY21 · Q2
2021-08-12
Zevra Therapeutics, Inc. (ZVRA) Q2 2021 Earnings Call Transcript
Revenue
$11.99M
▲ 73.5% YoY Diluted EPS
$-0.40
▼ 290.5% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY21 · Q1
2021-05-13
Zevra Therapeutics, Inc. (ZVRA) Q1 2021 Earnings Call Transcript
Revenue
$12.12M
▲ 480% YoY Diluted EPS
$-2.49
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY20 · Q4
2021-03-11
Zevra Therapeutics, Inc. (ZVRA) Q4 2020 Earnings Call Transcript
Revenue
$2.37M*
Rev · 8q
Audio
Transcript
Slides
8-K10-K
Earnings call
FY20 · Q3
2020-09-30
Zevra Therapeutics, Inc. (ZVRA) Q3 2020 Earnings Call Transcript
Revenue
$1.93M
▼ 83.2% YoY Diluted EPS
$-0.68
▼ 170.8% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY20 · Q2
2020-08-12
Zevra Therapeutics, Inc. (ZVRA) Q2 2020 Earnings Call Transcript
Revenue
$6.91M
Diluted EPS
$0.21
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY20 · Q1
2020-05-12
Zevra Therapeutics, Inc. (ZVRA) Q1 2020 Earnings Call Transcript
Revenue
$2.09M
Diluted EPS
$-1.92
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Showing 1–29 of 29 earnings calls